Evidence map›Paper›PMID 37598115›Full record

ArticleAnnals of surgical oncology2023

LncRNA EBLN3P Facilitates Osteosarcoma Metastasis by Enhancing Annexin A3 mRNA Stability and Recruiting HuR.

Shengtao Wang, Xinxin Zeng, Peng Gui, Shujuan Xu, Zhaoxu Li, Dongxu Chen

Open access · hybridAbstract read
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Shengtao WangDepartment of Joint Surgery and Sports Medicine, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Xiangshan District, Guilin, Guangxi, China.
Xinxin ZengDepartment of Pain, Banan Hospital of Chongqing Medical University, Banan District, Chongqing City, China.
Peng GuiDepartment of Trauma orthopedics and hand surgery, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Xiangshan District, Guilin, Guangxi, China.
Shujuan XuDepartment of Hematopathology, Affiliated Hospital of Guilin Medical University, Xiufeng District, Guilin, Guangxi, China.
Zhaoxu LiDepartment of Joint Surgery and Sports Medicine, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Xiangshan District, Guilin, Guangxi, China. lzxpds@126.com.ORCID http://orcid.org/0000-0002-1823-4855
Dongxu ChenDepartment of Joint Surgery and Sports Medicine, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Xiangshan District, Guilin, Guangxi, China. dongxuchenchen@163.com.
Nanxi Mountain Hospital · CNChongqing Medical University · CNGuilin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteosarcoma (OS) represents a common type of bone cancer. Long non-coding RNAs (LncRNAs) have shown their potential in therapeutic modalities for OS. This study's purpose was to reveal the action of lncRNA EBLN3P on OS growth and metastasis and its mechanism.

methodsExpressions of EBLN3P/Hu antigen R (HuR)/Annexin A3 (ANXA3) were determined by RT-qPCR/Western blot. Proliferation/migration/invasion of OS cells were assessed via CCK-8/Transwell assays after interfering EBLN3P/ANXA3/HuR. The co-localization of EBLN3P/ANXA3/HuR cells was observed by FISH/immunofluorescence assays. Interplays among EBLN3P/ANXA3/HuR and the half-life period of ANXA3 were assessed by RNA immunoprecipitation/RNA pull-down/RNA stability experiment. The nude mouse xenograft model was established, followed by EBLN3P treatment to assess the function of EBLN3P on OS.

resultsEBLN3P/ANXA3 was highly expressed in OS cells. Silencing EBLN3P or ANXA3 limited the proliferation/migration/invasion of OS cells. Mechanically, EBLN3P/ANXA3 can bind to HuR, and EBLN3P enhanced ANXA3 mRNA stability by recruiting HuR, thus facilitating OS cell growth. Upregulated HuR or ANXA3 counteracted the suppressive action of silencing EBLN3P on OS cells. In vivo experiments revealed facilitated tumor growth and metastasis in vivo fomented by EBLN3P through manipulation of HuR/ANXA3.

conclusionsEBLN3P enhanced proliferative/migrative/invasive potentials of OS cells via increasing ANXA3 mRNA stability and protein level by recruiting HuR, which provided new potential therapeutic targets for OS clinical treatment. EBLN3P and ANXA3 might have potential roles in OS diagnosis, treatment, and prognosis. This study provided a theoretical reference for further clinical research in tumor surgery.

Indexed as

Bone NeoplasmsOsteosarcomaRNA, Long NoncodingAnimalsAnnexin A3Cell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMiceAnnexin A3RNA, Long NoncodingAnnexin A3HuRInvasionLncRNA EBLN3PMetastasisMigrationOsteosarcomaProliferation

Identifiers

PMID37598115
PMCPMC10625973
OpenAlexW4385999477

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.